These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23375793)

  • 1. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
    Pike KG; Malagu K; Hummersone MG; Menear KA; Duggan HM; Gomez S; Martin NM; Ruston L; Pass SL; Pass M
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1212-6. PubMed ID: 23375793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.
    Pike KG; Morris J; Ruston L; Pass SL; Greenwood R; Williams EJ; Demeritt J; Culshaw JD; Gill K; Pass M; Finlay MR; Good CJ; Roberts CA; Currie GS; Blades K; Eden JM; Pearson SE
    J Med Chem; 2015 Mar; 58(5):2326-49. PubMed ID: 25643210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
    Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
    Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q; Song XM; Ji YY; Jiang H; Xu LG
    Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
    Sini P; James D; Chresta C; Guichard S
    Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
    English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
    Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
    Willems L; Chapuis N; Puissant A; Maciel TT; Green AS; Jacque N; Vignon C; Park S; Guichard S; Herault O; Fricot A; Hermine O; Moura IC; Auberger P; Ifrah N; Dreyfus F; Bonnet D; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Leukemia; 2012 Jun; 26(6):1195-202. PubMed ID: 22143671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
    Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
    Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
    Chresta CM; Davies BR; Hickson I; Harding T; Cosulich S; Critchlow SE; Vincent JP; Ellston R; Jones D; Sini P; James D; Howard Z; Dudley P; Hughes G; Smith L; Maguire S; Hummersone M; Malagu K; Menear K; Jenkins R; Jacobsen M; Smith GC; Guichard S; Pass M
    Cancer Res; 2010 Jan; 70(1):288-98. PubMed ID: 20028854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
    Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
    Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
    Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting.
    Altman JK; Szilard A; Goussetis DJ; Sassano A; Colamonici M; Gounaris E; Frankfurt O; Giles FJ; Eklund EA; Beauchamp EM; Platanias LC
    Clin Cancer Res; 2014 May; 20(9):2400-9. PubMed ID: 24610825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.